Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
iTeos Therapeutics, Inc. (ITOS)
|
Add to portfolio |
|
|
|
| Price: |
$42.00
| | Metrics |
| OS: |
35.8
|
M
| |
-5
|
% ROE
|
| Market cap: |
$1.5
|
B
| |
-10
|
% ROIC
|
|
Net cash:
|
$216
|
M
| |
$6.04
|
per share
|
|
EV:
|
$1.29
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($64.5)
|
M
| |
|
|
|
EBIT
|
($65.4)
|
M
| |
|
|
| EPS |
($0.83)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 267.6 | 344.8 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -22.4% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 267.6 | 344.8 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | | | |
| Selling, general and administrative | 141.3 | 99.9 | 45.2 | | |
| Research and development | | | | 19.2 | 17.2 |
| General and administrative | | | | 8.8 | 4.3 |
| EBIT | 126.3 | 244.9 | 0.0 | -27.0 | -21.5 |
| EBIT margin | 47.2% | 71.0% | | | |
| Pre-tax income | 148.7 | 256.5 | -38.1 | -22.3 | -18.0 |
| Income taxes | 52.1 | 41.9 | -0.1 | 0.1 | 0.0 |
| Tax rate | 35.0% | 16.4% | 0.1% | | |
| Net income | 96.7 | 214.5 | -38.0 | -26.5 | -18.1 |
| Net margin | 36.1% | 62.2% | | | |
| |
| Diluted EPS | $2.56 | $5.68 | ($2.88) | ($130.85) | ($29.36) |
| Shares outstanding (diluted) | 37.8 | 37.8 | 15.1 | 0.2 | 0.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|